What Needs To Be True To Buy Elevance Health Stock?
For questions about this article or underlying research, email help@trefis.com.
Elevance Health (ELV) stock returned about 40% over the past year, against about 15% for the S&P 500. A buyer today therefore comes in after a strong run. The stock rose 4.9% on November 4, the day after the midterm elections, as health insurer stocks jumped. On October 21, the company raised its 2026 earnings outlook after third-quarter results beat its own forecast. The catch lies in how an insurer earns money: it collects premiums, pays most of them out in medical claims, and keeps what is left. So how much of what Elevance collects does it actually keep?
Elevance Keeps Very Little Of Each Dollar It Collects
Over the twelve months to September 30, 2026, Elevance recorded a net margin of 2.5%, compared with 13.4% for the S&P 500. Most of what Elevance takes in goes directly toward members’ care. Management said the benefit expense ratio, which measures the share of premiums paid out in medical claims, was 90.6% in fiscal Q3 2026, an improvement of 70 basis points.
Elevance’s profit is very sensitive to medical costs. For example, consider an insurer that pays ninety cents in claims out of every premium dollar. If claims rise by one cent, a tenth of what it had left for running costs and profit is gone.
Are Elevance’s Medicare And Medicaid Margins Back On Target?
By management’s own account, they are not there yet. Elevance expects a full-year operating margin of at least 2% in Medicare Advantage, against its long-term target range of 3% to 5%. Management called 2026 the trough for its Medicaid margin and expects it to improve in 2027. Over time, management sees 2% to 4% as the right Medicaid margin.
Medicaid is also where the clearest risk sits. On the October 21 call, management said rates have not fully caught up with the underlying cost of care, and that the pace of recovery depends mainly on how quickly they do. A buyer today is betting that those rates catch up.
What Are You Paying For Elevance’s Earnings?
Elevance trades at 18.3 times its earnings over the past twelve months, against 22.8 for the S&P 500. Part of the latest quarter’s profit came from outside day-to-day operations. Management recorded a net non-operating benefit of $1.85 per share in fiscal Q3 2026, coming mainly from valuation adjustments within investment income.
Management set two figures for 2026: adjusted earnings of at least $29 per share, which includes favorable non-operating items, and a baseline of at least $26.75. The company expects adjusted earnings per share to grow at least 12% in 2027 from that baseline, and management said it is not relying on any single business to get there. Growth of 12% on $26.75 gives about $29.96 a share, just above the $29 figure for 2026.
Elevance is expected to report next in January 2027. Management said it will give more detail in January on its assumptions for 2027. The figures to watch in that report are the benefit expense ratio and management’s 2027 earnings outlook. For a buyer, three things need to be true: Medicaid rates must catch up with costs, margins must move toward management’s targets, and the 2027 growth plan must hold.
Now You Know Elevance Health. Here Is A Better Way To Invest
Before you decide on ELV, consider owning 30 quality companies instead of one. The Trefis High Quality (HQ) Portfolio has returned 105% since its September 2020 launch, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000.
Spot an error or want more like this? Tell us in 10 seconds.